Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:20am, Wednesday, 30'th Oct 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
04:05pm, Thursday, 24'th Oct 2024
—Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J. , Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical comp
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
08:00am, Wednesday, 23'rd Oct 2024
Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed I
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 17'th Oct 2024
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
08:00am, Thursday, 17'th Oct 2024
BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to d
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 04'th Oct 2024
BRIDGEWATER, N.J. , Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
These 12 Stocks are Ripe for a Short Squeeze
10:51am, Tuesday, 10'th Sep 2024
Subscribers to Chart of the Week received this commentary on Sunday, September 8.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 06'th Sep 2024
BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach
05:31pm, Wednesday, 28'th Aug 2024
Insmed Incorporated's Q2 2024 revenue grew by 17% year-over-year, reaching $90.3 million, driven by strong ARIKAYCE sales. The company is preparing for the U.S. launch of brensocatib in mid-2025, pend
Insmed Stock Surges 168% in the Past Six Months: Here's Why
12:10pm, Tuesday, 27'th Aug 2024
Shares of INSM soar after it reports positive data from two clinical studies that highlight its encouraging progress with its lung disorder drugs.
Meta Stock Leads 5 Names Near Buy Points As Market Bounces
08:00am, Saturday, 24'th Aug 2024
Meta leads five stocks near buy points as the market rallied Friday on Fed Chair Jerome Powell's speech.
Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript
04:11pm, Friday, 09'th Aug 2024
Insmed Incorporated (NASDAQ:INSM ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Offic
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
12:47pm, Friday, 09'th Aug 2024
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics
10:35am, Thursday, 08'th Aug 2024
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street es
